

531 Rec'd PC / 019087
19 DEC 2001

Attorney's Docket No. 9250-5CTIP4XX

PATENT #2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Fischer et al.

International Appl. No.: PCT/US01/18611

International Filing Date: 8 June 2001

For: METHOD FOR DETECTING A LIPOPROTEIN-ACUTE PHASE PROTEIN
COMPLEX AND PREDICTING AN INCREASED RISK OF SYSTEM FAILURE
OR MORTALITY

Date: December 19, 2001

BOX PCT

Commissioner for Patents


Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. The Commissioner is hereby authorized to charge any additional fee, which may be required, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,



Robert W. Glatz

Registration No. 36,811

Customer Number:



20792


PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No.: EV015664094US

Date of Deposit: December 19, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner of Patents, Washington, DC 20231.



Michele P. McMahan Date of Signature: December 19, 2001

531 Rec'd ST/TT

19 DEC 2001

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
9250-5CTIP4XX

Serial No.
To Be
Assigned

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

10/019087

Applicants:

Fischer et al.

Filing Date:

Concurrently Herewith

Group

Unknown

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1	4,782,014	11/01/88	Serban et al.	435	7	
	2	4,902,630	02/20/90	Bennett et al.	436	546	
	3	5,003,065	03/26/91	Merritt et al.	540	469	
	4	5,221,628	06/22/93	Anderson et al.	436	5074	
	5	5,358,852	10/25/94	Wu	435	7.94	
	6	5,500,345	03/19/96	Soe et al.	435	7.1	
	7	5,593,897	01/14/97	Potempa et al.	436	507	
	8	6,040,147	03/21/00	Ridker et al.	435	7.24	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	9	EP 818 680	01/14/98	EP	G01N	33/546	
	10	JP 04-254760	09/10/92	Japan - Abstract	G01N	33/53	
	11	WO 89/09628	10/19/89	WIPO			
	12	WO 91/00872	01/24/91	WIPO	C07K	15/28	
	13	WO 91/05874	05/02/91	WIPO	C12Q	1/00	
	14	WO 93/09438	05/13/93	WIPO	G01N	33/68	
	15	WO 93/24530	12/09/93	WIPO	C07K	15/06	
	16	WO 96/06624	03/07/96	WIPO	A61K	35/16	
	17	WO 97/04317	02/06/97	WIPO	G01N	33/68	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	18	Artherotech, <i>VAP/CAD Lipoprotein Risk Assessment Test and Sample of VAP Profile</i> , http://www.artherotech.com/risk_assesment.html					
	19	Cabana, et al., <i>Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins</i> , <i>LLipid Res.</i> , 30:39-49 (1989).					
	20	Cabana, et al., <i>Inflammation-induced changes in rabbit CRP and plasma lipoproteins</i> , <i>LIimmunol.</i> , 130(4):1736-1742 (April 1983).					

EXAMINER

*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney: 531 Res' drc 9250-5CTIP4XX <div style="text-align: right;"> 19 DEC 2001 To Be Assigned 10/019087 </div>	
		Applicants: Fischer et al.	
		Filing Date: Concurrently Herewith	Group Unknown
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	21	Cabana, et al., <i>Interaction of very low density lipoproteins (VLDL) with rabbit C- reactive protein</i> , <u>L.Immunol.</u> , 128(5):2342-2348 (May 1982).	
	22	Canivet, et al., <i>Postoperative changes in lipid profile: their relations with inflammatory markers and endocrine mediators</i> , <u>Acta Anaesthesiol.Belg.</u> , 40(4):263-268 (1989).	
	23	Christner and Mortensen, <i>Specificity of the binding interaction between human serum amyloid P- component and immobilized human C-reactive protein</i> , <u>L.Biol.Chem.</u> , 269(13):9760-9766 (April 1994).	
	24	de Beer, et al., <i>Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein</i> , <u>L.Exp.Med.</u> , 156:230-242 (July 1982).	
	25	Dennis et al., <i>Utility of prothrombin time waveform analysis in the routine clinical setting</i> , <u>Abstract Instruction and Submission Form</u> , (Sept. 1999).	
	26	Downey et al., <i>The robustness and reproducibility of APTT waveform analysis in relation to reagent and batch variation</i> , <u>abstract only</u> .	
	27	Downey et al., <i>Transmittance waveforms - adjunctive information from automated coagulometers</i> , <u>Int.J.Hematol.</u> , 64 Suppl:S160, Abstract #619, (Aug. 1996).	
	28	Downey, et al., <i>Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation</i> , <u>Br.J.Haematol.</u> , 98:68-73 (1997).	
	29	Eitoku et al. et al., <i>Studies on the serum amyloid A (SAA): Part 2 latex agglutination nephelometric immunoassay system for the quantitation of SAA in human serum and its clinical values</i> , <u>Physico.Chem.Biol.</u> , 37:19-23 (Feb. 1993).	
	30	Engler, R., <i>[Acute-phase proteins in inflammation]</i> , <u>C.R.Seances Soc.Biol.Fil.</u> , 189(4):563-578 (1995).	
	31	Gewurz, et al., <i>C-reactive protein and the acute phase response</i> , <u>Adv.Intern.Med.</u> , 27:345-372 (1982).	
	32	Harris et al., <i>Reactivity of serum amyloid P component with C-reactive protein and IgM</i> , <u>Clin.Res.</u> , 37, Abstract #614A (1989).	
	33	Hulman and Fuller, <i>Comparison of fat agglutination slide test and latex test for C- reactive protein</i> , <u>Clin.Chim.Acta</u> , 165:89-93 (5-29-1987).	
	34	Hulman, et al., <i>Agglutination of intralipid by sera of acutely ill patients</i> , <u>Lancet</u> , 2:1426-1427 (Dec. 1982).	
	35	Hulman, G., <i>The pathogenesis of fat embolism</i> , <u>L.Pathol.</u> , 176:3-9 (1995).	
	36	Husebekk, et al., <i>High-density lipoprotein has different binding capacity for different apoproteins. The amyloidogenic apoproteins are easier to displace from high-density lipoprotein</i> , <u>Scand.J.Immunol.</u> , 28:653-658 (1988).	
	37	Lagrand, et al., <i>C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?</i> , <u>Circulation</u> , 100:96-102 (July 1999).	

 EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney's Office Number 521 Resub CT 9250-5CTIP4XX Serial No. 19 DEC 2001 To Be Assigned 10/019087	
		Applicants:	
		Fischer et al.	
		Filing Date:	Group
		Concurrently Herewith	Unknown
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	38	Lindh, et al., <i>Agglutinate formation in serum samples mixed with intravenous fat emulsions</i> , <u>Crit Care Med.</u> , 13(3):151-154 (March 1985).	
	39	Malle, et al., <i>Serum amyloid A (SAA): an acute phase protein and apolipoprotein</i> , <u>Atherosclerosis</u> , 102:131-146 (1993).	
	40	Maury et al., <i>Clinical usefulness of serum amyloid A and C-reactive protein measurements in inflammatory disorders a comparative study</i> , <u>Marker Proteins in Inflammation Proceedings, Symposium, Lyon, France</u> , 3:Abstract only-(1985), 153-156	
	41	McCarty, M., <i>Historical perspective on C-reactive protein</i> , <u>Ann.N.Y.Acad.Sci.</u> , 389:1-10 (1982).	
	42	McDonald, et al., <i>A monoclonal antibody sandwich immunoassay for serum amyloid A (SAA) protein</i> , <u>J.Immunol.Methods</u> , 144:149-155 (11-22-1991).	
	43	Pepys, et al., <i>C-reactive protein: binding to lipids and lipoproteins</i> , <u>Int.Rev.Exp.Pathol.</u> , 27:83-111 (1985).	
	44	Preciado-Pratt et al. et al., <i>Serum amyloid A complexed with extracellular matrix induces the secretion of tumor necrosis factor-alpha by human T-lymphocytes</i> , <u>Letters in Peptide Science</u> , 5:349-355 (Oct. 1988).	
	45	Richter, et al., <i>The fat emulsion agglutination test: a reliable and cost effective alternative to the latex agglutination test for rapid bedside CRP measurement</i> , <u>Clin.Chim.Acta</u> , 261:141-148 (May 1997).	
	46	Robin et al., <i>Prognostic value of waveform analysis in the intensive care setting</i> , <u>Intensive Care Med.</u> , 25(Suppl 1):S63 (1999).	
	47	Rowe, et al., <i>Agglutination of intravenous lipid emulsion ('Intralipid') and plasma lipoproteins by C-reactive protein</i> , <u>Clin.Exp.Immunol.</u> , 66:241-247 (1986).	
	48	Rowe, et al., <i>Circulating human C-reactive protein binds very low density lipoproteins</i> , <u>Clin.Exp.Immunol.</u> , 58:237-244 (1984).	
	49	Rowe, et al., <i>In vivo turnover studies of C-reactive protein and lipoproteins in the rabbit</i> , <u>Clin.Exp.Immunol.</u> , 58:245-252 (1984).	
	50	Rowe, et al., <i>Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins</i> , <u>J.Exp.Med.</u> , 159:604-616 (Feb. 1984).	
	51	Rybarska, J., Konieczny, L., Piekarska, B., Stopa, B., and Roterman, I. et al., <i>The detection of specific acute phase serum protein complexes and immune complexes by congo red binding</i> , <u>J.Physiol Pharmacol.</u> , 46(2):221-231 (June 1995).	
	52	Sammalkorpi, et al., <i>Lipoproteins and acute phase response during acute infection. Interrelationships between C-reactive protein and serum amyloid-A protein and lipoproteins</i> , <u>Ann.Med.</u> , 22:397-401 (1990).	

 EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

531 Recd CT

19 DEC 2001

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number 9250-5CTIP4XX 10/019087	Serial No. To Be Assigned 10/019087
		Applicants: Fischer et al.	
		Filing Date: Concurrently Herewith	Group Unknown
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	53	Schwalbe, et al., <i>Association of rat C-reactive protein and other pentraxins with rat lipoproteins containing apolipoproteins E and A1</i> , <i>Biochemistry</i> , 34(33):10432-10439 (Aug. 1995).	
	54	Simmons, A. <i>Ethanol-gel solubility test</i> , In: <i>Technical Hematology</i> , 3rd Edition, J.B. Lippincott Company, Philadelphia, PA, pg. 334-335 (1980).	
	55	Stewart, et al., <i>Sensitive and rapid measurement of C-reactive protein (CRP) by lipid agglutination</i> , <i>J.Clin.Pathol.</i> , 40:585-588 (1987).	
	56	Swanson, et al., <i>Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP)</i> , <i>Biochim.Biophys.Acta</i> , 1160:309-316 (12-28-1992).	
	57	Toh and Downey, <i>A previously unrecognized mechanism that is calcium-dependent and thrombin-independent characterizes the pre-DIC state</i> , <i>The American Society of Hematology, 1999 Submission Form</i> , Abstract #450426 (1999).	
	58	Toh and Downey, <i>The mechanism underlying the atypical clot waveform profile of DIC is thrombin-independent but calcium-dependent</i> , <i>European Haematology Association, Abstract Form</i> (June 2000).	
	59	Toh et al., <i>APTT Waveform analysis: predicting mortality in the critical care setting using the light transmittance level at 18 seconds</i> , <i>XVII Congress International Society for Thrombosis & Haemostasis, Abstract Submission Form</i> , (Aug. 1999).	
	60	Toh et al., <i>Characterization of the novel calcium-activation, thrombin suppression assay (CaTs) in the DIC of sepsis, abstract only</i> .	
	61	Toh et al., <i>Impending clinical decompensation is characterized by the detection of a novel calcium-dependent and thrombin-independent pathway</i> , <i>5th World Congress on Trauma, Shock, Inflammation and Sepsis -- Pathophysiology, Immune Consequences and Therapy, Abstract Submission Form</i> , (Feb. 2000).	
	62	Toh et al., <i>Prospective detection of pre-disseminated intravascular coagulation (DIC) in a sepsis cohort by waveform analysis</i> , <i>XVII Congress International Society for Thrombosis & Haemostasis, Abstract Submission Form</i> , (Aug. 1999).	
	63	Toh et al., <i>Waveform analysis of the prothrombin time (PT) assay also shows characteristic changes in disseminated intravascular coagulation</i> , <i>XVII Congress International Society for Thrombosis & Haemostasis, Abstract Submission Form</i> , (Aug. 1999).	
	64	Toh, C.H., <i>Disseminated intravascular coagulation (DIC): Old problem, new hope</i> , <i>Clin.Hemostasis Rev.</i> , pg 18 (Jan. 1998).	
	65	Wilkins, et al., <i>Rapid automated enzyme immunoassay of serum amyloid A</i> , <i>Clin.Chem.</i> , 40(7):1284-1290 (1994).	

 EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.